Dose-response curve and time course of the antihypertensive effect of SKF 92 657, a beta-receptor-blocking and vasodilating compound.

Abstract

1. The antihypertensive effect of the new drug, SKF 92 657, a hydrazinopyridazine derivative, possessing both beta-adrenoreceptor-blocking and vasodilating properties, was investigated in essential hypertension. 2. Single oral doses of 1.0 or 2.0 mg/kg did not produce any consistent decrease in blood pressure; 4.0 mg/kg was the threshold dose for a mild but not significant blood pressure reduction, whereas 8.0 mg/kg caused a significant and marked blood pressure decrease without clinically relevant changes in heart rate. 3. Continued administration of the drug for 7 days induced a significant and uniform reduction in blood pressure without tachycardia. The increase in systolic blood pressure and in heart rate caused by dynamic exercise was left unaffected by the drug.

• Authors: G Leonetti, L Terzoli, C Sala, C Bianchini, A Zanchetti
• Journal: Clinical science (London, England : 1979) (Clin Sci (Lond)) Vol. 59 Suppl 6 Pg. 461s-463s (Dec 1980) ISSN: 0143-5221 [Print] England
• PMID: 6108817 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Adrenergic beta-Antagonists
• Hydrazines
• Pyridazines
• Vasodilator Agents
• prizidilol

Topics

• Adrenergic beta-Antagonists (therapeutic use)
• Dose-Response Relationship, Drug
• Drug Evaluation
• Humans
• Hydrazines (therapeutic use)
• Hypertension (drug therapy)
• Male
• Middle Aged
• Posture
• Pyridazines (therapeutic use)
• Time Factors
• Vasodilator Agents (therapeutic use)